Trial Profile
A Prospective Open-label Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs RT 001 (Primary)
- Indications Neuroaxonal dystrophies
- Focus Registrational; Therapeutic Use
- Sponsors Retrotope
- 26 Apr 2022 Primary endpoint Modified Ashworth Spasticity Scale has not been met, according to Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 06 Oct 2021 According to a Retrotope media release, Darius J. Adams and Alex Fay are the principal investigator of this trial.